Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease; CREDO 2

Prensa/medios de comunicación

Período2 oct. 2018

Cobertura de los medios

1

Cobertura de los medios

  • NombreEvaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease; CREDO 2
    Nombre/canal del medio de comunicaciónClinical Trials.gov
    Fecha2/10/18
    PersonasDiego Luis Saaibi Solano